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H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sr e l a t i v e l yc o m m o na m o n gp a tients with end-stage kidney disease (ESKD) on dialysis and
kidneytransplantrecipients.HCV infectioninhemodialysispatientsis associatedwithanincreasedmortalitydueto liver cirrhosis
and hepatocellular carcinoma. The severity of hepatitis C-related liver disease in kidney transplant candidates may predict patient
and graft survival after transplant. Liver biopsy remains the gold standard in the assessmentof liver ﬁbrosis in this setting. Kidney
transplantation, not haemodialysis, seems to be the best treatment for HCV+ve patients with ESKD. Transplantation of kidneys
from HCV+ve donors restricted to HCV+ve recipients is safe and associated with a reduction in the waiting time. Simultaneous
kidney/liver transplantation (SKL) should be considered for kidney transplant candidates with HCV-related decompensated
cirrhosis. Treatment of HCV is more complex in hemodialysis patients, whereas treatment of HCV recurrence in SLK recipients
appears eﬀective and safe.
1.Introduction
Hepatitis C is one of the commonest chronic viral infections
world-wide and has major healthcare and health economic
implications [1]( Figure 1). However, with recent advances
in treatment, clearance of the virus is achieved in selected
cases and a reduction in the rate of progression of liver
diseaseanditscomplicationsoccursinothers.Kidneydisease
is a major public health problem; over 10% of the adult
population has chronic kidney disease (CKD) [2], and up
to 350pmp/yr of the adult population develop ESKD and
require treatment with renal replacement therapy (RRT) by
dialysis or transplantation. The prevalence of HCV infection
in people with ESKD is very high, and when present
has implications both for dialysis patients and for kidney
transplant (KT) recipients [3, 4].
HCVinfectionischallengingbothindialysispatientsand
KT recipients, but there are diﬀerences between these two
groups in terms of the eﬀect of HCV infection on long-term
survival, the natural history of the disease, and diﬀerential
beneﬁts and risks associated with available treatments both
of the HCV and the renal failure. As kidney transplanta-
tion is the treatment of choice for many people with ESKD,
the clinical assessment and the management of HCV infec-
tion are important clinical considerations in this setting.
In this paper, we report the current status of HCV infec-
tion and kidney transplantation. After a brief presentation of
the natural history of hepatitis C virus infection in immuno-
competent host, we assess: (i) HCV infection in end-stage
kidney disease (ii) the impact of HCV on clinical outcomes
(iii) the assessment of the disease and (iv) the disease man-
agement of HCV+ve kidney transplant recipients.
2.NaturalHistoryofHepatitisCVirus
(HCV) Infection
The worldwide burden of chronic hepatitis C (CHC) infec-
tion is enormous. In 1999, the World Health Organization
estimatedthattheworldwideprevalenceofCHCrangesfrom
0.1% to more than 12%. This equates to approximately 170
million chronic carriers worldwide with an incidence of 3 to
4 million new cases annually [6].
After initial exposure, HCV RNAcan be detected inblood
within 1 to 3 weeks. Acuteinfection is usually asymptomatic;
it can be severebutrarely fulminant. In general, 60 to 85% of2 International Journal of Nephrology
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Figure 1: Prevalence of Hepatitis C Infection. Data source: World
Health Organization. (Modiﬁed from [5].)
HCV-infected persons develop chronic infection, deﬁned as
the continued presence of HCV RNA for 6 months or longer
after the estimated onset [7].
The spectrum of the disease ranges from mild to severe
chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
The disease is complex, and predictions about long-term
prognosis for individual patients remain diﬃcult. Hepatitis
C can be extremely slow to progress and usually does so
without liver-speciﬁc symptoms or physical signs during
the ﬁrst decade of infection. Estimates of the proportion
of chronically infected persons who develop cirrhosis 20
years after initial infection vary from 10 to 15% [7]. When
liver cirrhosis is established, thetransition to decompensated
cirrhosis occurs when complications secondary to liver
failure arise, such as jaundice, variceal hemorrhage, ascites,
and encephalopathy. Decompensated cirrhosis is associated
with increased risk of mortality and necessitates liver trans-
plantation.
Identifying the group of patients at greatest risk of ﬁbro-
sis progression remains a primary challenge for clinicians.
Older age at time of infection, duration of infection, degree
of liver inﬂammation at ﬁrst biopsy, and cofactors such as
alcohol abuse and coinfection with human immunodeﬁ-
c i e n c yv i r u s( H I V )o rh e p a t i t i sBv i r u s( H B V )a l la p p e a rt o
be predictors of a poorer prognosis.
The most reliable tools for examining the natural history
of hepatitis C are those which examine a change in the
histopathological status. Although this necessitates repeated
liver biopsies, it does enable the physician, within the space
of a few years, to examine possible disease progression
or lack of it. The typical histological features of chronic
hepatitisCarevariabledegreesofhepatocellularnecrosisand
inﬂammation, referred to as the activity or grade of disease,
and ﬁbrosis, referred to as stage of disease.
While the activity of the liver disease can ﬂuctuate, ﬁbro-
sis is believed to be progressive and largely irreversible.
Importantly, it is the progression of ﬁbrosis that ultimately
leads to architectural distortion of the liver and cirrhosis.
For these reasons, the rate of progression of ﬁbrosis is the
deﬁning feature of the natural history of chronic hepatitis C.
Several systems for scoring liver ﬁbrosis have been pro-
posed, each based on visual assessment of collagen staining
ofliverbiopsysamples,andthemorefrequentlyusedsystems
are the histology activity index (HAI: Knodell score) [8, 9]
and the Metavir system [10].
In 2001, Poynard reported that the median estimated
duration of infection for progression to cirrhosis was 30
years, ranging from 13 years in men who drank and were
infected after the age of 40 to 42 years in women who did
not drink alcohol and were infected beforethe age of 40 [11].
This average rate of progression of ﬁbrosis is consistent with
those reported in more recent studies [12–14]. It should be
highlighted, however, that these studies were performed in
referral centers, and the patients who were studied may not
have been representative of the average patient with chronic
hepatitis C.
3.HCV InfectioninEnd-StageKidneyDisease
(ESKD):Prevalenceand ImpactonSurvival
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sv e r yc o m m o ni np a -
tientswithESKD[15].The reported prevalenceinhemodial-
ysis(HD)patientsisvariable,butisconsiderablygreaterthan
in the general population. There are some indications that
the overall prevalence of HCV infection in dialysis patients is
falling, as reported by data from the USA, Western Europe,
and Australia and New Zealand [3, 16–19].
Information on the incidence and prevalence of HCV
infection in patients on long-term dialysis in developing
countries islimited,butsingle-centersurveysshowthatthese
rates are high [20–22]. This probably reﬂects nosocomial
transmission of HCV in the HD environment, incomplete
anti-HCV screening of blood and blood products, and a
higherprevalenceofHCVinthegeneralpopulationindevel-
oping countries.
I rr es pecti v eofthebas elinepr evalenc einthegeneralpop-
ulation, the key underlying determinants of an increased
relative risk of HCV infection in dialysis patients are age,
overall exposure to blood products, and the duration of
dialysis treatment [15–17]. Therefore, the widespread use of
erythropoeisis-stimulating agents (ESAs) with a consequent
decrease in blood transfusions and progressive improve-
ments in infection control on dialysis units are likely major
contributors to a decreasing prevalence of HCV infections in
HD patients in the developed world.
In those patients who undergo renal transplantation, in
developed countries, the reported prevalence of HCV infec-
tion is usually higher than that seen in HD patients, ranging
from 11% to 49% [23–30].
W h e r et h e r ea r ed i ﬀerences reported in HCV infection
prevalence between dialysis patients and KT recipients, the
reasons may include the length of time on dialysis before
transplantation, the duration of the dialysis that the trans-
plant recipient received, and a history of and/or the num-
ber of blood transfusions. As transplant recipients usuallyInternational Journal of Nephrology 3
Table 1:SummaryEstimatesforAdjustedRelativeRiskofMortality
amongHCV+ve Dialysis Patients.
Cohort Size RR P-value
Goodkin et al. [4] 16 720 1.17 .016
Fabrizi et al. [31]∗ 2 341 1.57 —
Fabrizi et al. [33]∗∗ 11 589 1.34 —
Scott et al. [3] 23 046 1.25 .04
∗Meta-analysis of four clinical trials [34, 35]. A test for homogeneity of the
relative risks across the four studies gave a P-value of .77.
∗∗Meta-analysis of seven clinical trials [36]. Tests for homogeneity of the
aRR across the seven studies gave Ri value of 0.48.
RR: relative risk.
survive longer than patients who remain on dialysis, a higher
proportion of transplant recipients may have been exposed
as a consequence of receiving blood products or dialysis in a
period of less rigorous infection control.
HCV infection has been independently associated with
an increased mortality in maintenance HD patients. The
DOPPS (Dialysis Outcomes and Practice Patterns) study,
conducted over three continents, showed an independent
association between positive anti-HCV antibody status and
mortality in dialysis patients [4]. These results have been
conﬁrmed in other studies [31–33].
Scott et al. (the ANZDATA registry study) [3]r e p o r t e d
similar survival at 5 years (48% versus 47%) and 10 years
(22% and 20%) for HCVAb+ve and HCVAb−ve patients,
however, when the diﬀerentialage distribution and otherpa-
tient characteristics were incorporated, the adjusted hazard
ratio (aHR) for mortality was increased in the HCVAb+ve
population Table 1.
4.OutcomeofRenalTransplantationin
HCV+Patients
Kidney transplantation (KT) is associated with improved
long-term survival in the ESRD population [37], and whilst
there is evidence in some studies of a detrimental impact
of HCV infection on the outcome of KT, the survival of
HCV infected recipients is excellent when considered against
that those of HCV infected patients who remain on dialysis
[38, 39].
Initial studies focused on short-term outcomes and
showed similar patient and graft survival in HCV+ and
HCV−recipientsat5years[27,40–42],and alowprevalence
of cirrhosis HCV-related even after 10 years post-KT [43].
Similar ﬁndings were reported by Einollahi et al. in 2002,
who showed no diﬀerences in terms of survival between
HCV+ve and HCV−ve recipients at 7 years post-KT [44].
These ﬁndings could reﬂect the comparatively short
period of followup as well as the low numbers of patients
as some studies have indicated that the diﬀerence in survival
was signiﬁcant only in the second decade after transplanta-
tion [45].
These single studies were pooled by Fabrizi et al. in a
meta-analysis [46], which showed that positive anti-HCV
antibody status was an independent and signiﬁcant risk
factor for death and graft failure after renal transplantation;
the summary estimate for the relative risk was 1.79 (95%
CI, 1.57; 2.03) and 1.56 (95% CI, 1.35; 1.80), respectively
(Table 2).
In their recent study, Scott and colleagues [3]e v i d e n c e d
a prevalence of HCV infection among kidney transplant
recipients of 1.8%, and found that patient survival among
HCVAb+ve and HCVAb−ve groups was 77% versus 90%
and 50% versus 79% at 5 and 10 years, respectively,
with an adjusted HR for patient death of 2.38 (95%CI,
1.69–3.37).The most common causes of death among the
HCVAb+ve kidney recipients were cardiovascular disease
(aHR = 2.74), malignancy (aHR = 2.52), and hepatic failure
(aHR = 22.1).
Despite the negative impact of HCV infection on long-
term survival after KT,threeretrospective studies [34,39,53]
of HCV-infected patients have demonstrated that survival is
improved with transplantation compared to the remaining
wait-listed on dialysis in HCV-infected patients with kidney
failure. There are no published studies demonstrating a
worse outcome with transplantation compared to dialysis
for these patients. Therefore, it is recommended that HCV
infection should not be considered a contraindication to KT
[54].
While mortality is the most signiﬁcant end-point in
the natural history of HCV after KT, other outcomes have
also been assessed in HCV-infected KT recipients with
variable conclusions. In a case-control, retrospective survey,
Zylberbergetal.[55]foundthattheyearlyprogressionrateof
hepatic inﬂammation and ﬁbrosis was signiﬁcantly higher in
the KT recipients as compared with the immunocompetent
group.Incontrast,Alricetal.[56]foundthattheprogression
of liver ﬁbrosis per year was signiﬁcantly lower for KT
recipients than for matched patients with HCV and normal
renal function. Reasons for the diﬀerences are not clear.
4.1. De Novo Glomerulonephritis and Chronic Allograft
Nephropathy after Kidney Transplant in HCV+ve Recipient.
Inadditiontoanincreaseddiseaseburdenduetoliverdisease
and an association with all-cause and cardiovascular disease
mortality, HCV infection in kidney transplant recipients has
been implicated in the pathogenesis ofacute glomerulopathy
[57], de novo immune complex glomerulonephritis in the
allograft [58–60], and, in some reports, a higher rate of
chronic allograft nephropathy (CAN) [61].
HCV infection is one of the most important factors pre-
disposing to the development of glomerulonephritis (GN)
in the native kidney and in the renal allograft [62]a n dt h e
high prevalenceofHCVinfection inrenal allograft recipients
places this group at high risk of immune-mediated glomeru-
lar diseases. In de novo membranoproliferative glomeru-
lonephritis (MPGN) and de novo membranous glomeru-
lopathy (MGN), with or without mixed cryoglobulinemia,
are the most most frequent glomerular lesion associated with
chronic HCV infection in renal allografts [58, 60, 63].
In 2001, Cruzado et al. [64] reported a prevalence of de
novo MPGN and MGN in HCV+ve kidney recipients
of 45.4% and 18.2%, respectively, versus a lower rate in4 International Journal of Nephrology
Table 2: Death rate in HCV+ve versus HCV−ve patients after Kidney Transplantation.
Year of publication Followup after KT in
months (mean)∗ HCV-positive Death HCV-negative Death P-value
Pereira et al. [23] 1995 68/70 11/29 (38%) 26/72 (36%) n.s.
Pereira et al. [47] 1995 68/83 9/22 (41%) 16/78 (20.5%) n.s.
Legendre et al. [48] 1998 79/81 15/112 (13.4%) 19/387 (5%) .01
Gentil et al. [49] 1999 62/57 13/85 (15.3%) 11/235 (4.7%) .003
Lee et al. [50] 2001 72 31/151 (20.5%) 46/326 (14%) n.s.
Breitenfeldt et al. [51] 2002 110.4 38/130 (29%) 164/797 (20.6%) .001
Einollahi et al. [44] 2003 n.a. 2/41 (5%) 34/868 (4%) .74
Bruchfeld et al. [52] 2004 130 29/51 (57%) 170/520 (32.7%) .001
Scott et al. [3] 2010 62.4 32/140 (23%) 743/7432 (10%) .0001
∗Data are given for anti-HCV+ve/anti-HCV−ve patients when appropriate.
n.a.: not available; n.s.: not statisticallysigniﬁcant.
HCV−ve recipients of 5.7% and 7.7%, respectively. These
data have been conﬁrmed in 2006 by Ozdemir et al. [59]
who reported a prevalence of de novo GN in HCV-infected
recipients of 34%, compared to 6.6% in HCV−ve recipients.
In both studies, this higher prevalence of autoimmune GN
was associated with a poor graft outcome, even worse than
de novo GN in HCV−ve.
HCV infection has also been associated with CAN. This
was ﬁrst suggested in 2005 by Mahmoud who reported
a higher rate of CAN in patients HCV+ve who had not
received interferon therapy before KT, compared with a
population of HCV+ve patients who received IFN for the
treatment of HCV infection (with a 100% of biochemical
response and 55% ofclearanceof the virus), after controlling
for other biases that may contribute to the development
of CAN [61]. Recently, the analysis of the ANZDATA has
shown an increased rates of graft failure due to chronic
allograft nephropathy (aHR = 1.87) in HCV+ve recipients
compared to HCV−ve patients [3]; also, the analysis of 4304
renal transplant recipients (with 587 of them HCV+ve) in
the period 1990–2002, performed by the Spanish Chronic
Allograft Nephropathy Study Group [65], evidenced HCV
infection was associated with early greater rates of pro-
teinuria, lower renal function, chronic rejection, de novo
GN, graft loss, and lower survival, compared with HCV−ve
recipients.
The pathogenesis of CAN could be explained by a mul-
titude of alloantigen-dependent and -independent factors
which have been extensively reviewed [66–68].
It has been proposed that a higher incidence of acute
rejection due to higher viral-induced immune reactivity
according to previous studies [27] and a chronic suboptimal
immunosuppression might be a possible explanation for the
relationship betweenHCVinfectionandCAN.However,this
association has not been conﬁrmed in other studies [69].
HCV infection has also been associated with the devel-
opment of early graft dysfunction due to acute glomerular
lesions, such as acute transplant glomerulopathy and de
novo renal thrombotic microangiopathy [57, 70]. Hepatitis
C infection has also been linked to an increased incidence
of posttransplant diabetes mellitus (PTDM) [71], which
is an important determinant of worse outcome following
transplantation.
4.2. HCV Replication and Immunosuppression Regimen after
Kidney Transplant. Levels of viremia after transplantation
are higher compared to pretransplantation values [72]. The
marked increase in serum HCV-RNA levels, which usually
develops within the ﬁrst months after renal and liver trans-
plantation, has beencloselyassociated with the immunosup-
pressive therapy, and a more aggressive immunosuppression
enhances HCV replication [73], although the relationship
between posttransplantation viral kinetics and severity of
recurrence of HCV remains unclear.
Pelletier in 2000 found no correlation between HCV-
RNA blood levels and the intrahepatic viral replication rate
in the posttransplant period [74], suggesting that the ele-
vated levels of serum HCV-RNA typically observed post-
transplantation are not a result of increased replication but
rather of decreased clearance in the setting of immune sup-
pression [75].
DiMartino et al. [76] evidenced a progression to chronic
activehepatitisafterlivertransplantation, despiteareduction
in immunosuppression and a decrease of intrahepatic HCV-
RNA levels, suggesting an immune-mediated injury behind
the liverdamage, although there are reports ofan association
between high levels of viral replication and a rapid progres-
sive histologic course suggesting a cytopathic mechanism of
HCV-inducedallograftinjury[77–80].Highlevelsofviremia
have been described in the setting of ﬁbrosing cholestatic
hepatitis (FCH) after liver transplantation [81], suggesting
that during the early phase of recurrent hepatitis C or in
the setting of this particular syndrome, liver damage may
be due to the direct cytopathic eﬀect of HCV. Fibrosing
cholestatic hepatitis has been sporadically described in kid-
neytransplant recipientswithasevere,andoftenfatal,course
[82–85].
At the present time, there are relatively few studies that
examine the impact of immunosuppression on HCV-related
outcomes in kidney transplant patients, and it is not clear
whether the impact of immunosuppression on outcomes
in liver transplant patients with HCV infection can beInternational Journal of Nephrology 5
extrapolated to HCV-infected kidney transplant recipients.
Therefore, all currently available maintenance immunosup-
pressive therapiescanbe used in kidney transplant recipients
with HCV infection [54].
Cyclosporin, but not tacrolimus may inhibit HCV viral
replication, although whether this has any clinical con-
sequences is not validated in kidney transplant patients.
However, a recent report of 71 HCV+ve KT recipients [86]
showed, during long-term immunosuppression, cyclospo-
rine when compared with tacrolimus, resulted in no signif-
icant diﬀerencesin viral replication and developmentof liver
ﬁbrosis. However, the function of the renal graft was signiﬁ-
cantly better preserved in patients receiving tacrolimus.
Mycophenolate mofetil (MMF) has shown to have an
inhibitory eﬀect on viral replication in the nontransplant
setting [87] and there is no convincing evidence of a speciﬁc
deleterious eﬀect on either graft or patient outcomes in
kidney transplant recipients with HCV infection [88, 89].
Amongantibody therapiescommonlyusedforinduction
or for treating acute rejection, unfavorable outcomes have
been frequently reported in the literature concerning liver
transplant patients with HCV infection. In contrast, recent
registry data of 3708 patients from the United States indicate
that antibody induction with the use of a biological agent,
either depleting (OKT3, ATGAM, or rabbit thymoglobulin)
or nondepleting antibodies (IL-2 R blockingantibodies), did
not negatively aﬀect patient survival in HCV-infected kidney
transplant recipients [90].
Regarding the use of sirolimus in HCV-infected kidney
transplant recipients, there are only limited data.
5.Assessment ofLiverFibrosisinHCV+Renal
TransplantCandidates
There is evidence that the severity of hepatitis C-related liver
disease may predict worse patient and graft survival [91, 92]
after KT. The most accurate method to assess liver inﬂam-
mation and ﬁbrosis is with liver histology, using the Knodell
score [8]. Single-center retrospective cross-sectional studies
havereported thatupto 25%ofHCV-infected patientsbeing
evaluated for kidney transplantation have bridging ﬁbrosis
or cirrhosis on biopsy [93–98]. Some investigators have sug-
gestedthatpresenceofadvanced ﬁbrosis(bridgingﬁbrosisor
cirrhosis) should preclude kidney transplantation [99, 100].
However, we feel that currently there are insuﬃcient data to
support such a recommendation.
Recently, the accuracy of liver biopsy in staging liver
disease has been a focus of discussion. Because a biopsy rep-
resents1/50,000ofthe liver,the heterogeneityofliverﬁbrosis
in HCV infection and the inadequacy ofliver sample size can
cause considerable bias in the assessment of liver histology
[100–102]. Also, liver biopsy is associated with clinical risks.
Currently, a variety of noninvasive tests may be used
to estimate liver ﬁbrosis in HCV patients with normal
renal function, using either individual markers (such as
procollagen) or a panel of tests, such as the Enhanced Liver
Fibrosis (ELF) that includes hyaluronic acid, tissue inhibitor
of matrix metalloproteinases-1, aminoterminal propeptide
of procollagen type III (which are involved in the synthesis
and degradation of extracellular matrix) [103], and present
the advantage of providing frequent ﬁbrosis evaluation.
However, few data are available regarding the utility of those
tests in ESRD patients with HCV chronic infection (Table 3).
The AST/ALT ratio was studied as a noninvasive marker
of liver ﬁbrosis in 49 ESRD patients with HCV infection.
Despite the signiﬁcant diﬀerences in AST/ALT ratio found
between diﬀerent ﬁbrosis stages, the usefulness of this index
may be limited by the absence of adjusted cutoﬀsi nE S R D
patients where lower aminotransferase activity is expected.
The lack of association between AST/ALT ratio and the
degree of liver ﬁbrosis has been also conﬁrmed in a more
recent study [103, 108].
The FibroTest, a composite marker of ﬁbrosis, has been
evaluated in both HD patients and KT recipients with HCV
infection, but its reliability in this setting is controversial
[106, 107].
APRI (AST-to-platelets ration index) with adjusted cut-
oﬀs has been proposed as a valid alternative to liver biopsy
in a signiﬁcant proportion of HCV+ HD patients [103, 104]
although further large studies are needed to conﬁrm these
ﬁndings.
Others markers of liver ﬁbrosis have also been evaluated
in patients with chronic hepatitis C, including YKL-40 and
hyaluronic acid (HA), but the performance of these tests
was lower than that observed for others noninvasive markers
previously evaluated such as APRI [105].
Transient elastography (TE, FibroScan) is a novel non-
invasive technique that has been validated in patients with
chronic hepatitis C for the assessment of hepatic ﬁbrosis, by
measuring liver stiﬀness. Although it has not been validated
yet in CKD patients with HCV infection, it may represent a
new and noninvasive tool to assess the stage of liver disease
in this setting.
In conclusion, liver biopsy represents the gold-standard
in the assessment of liver ﬁbrosis in HCV+ patients with
ESKD and might be considered part of the pretransplant
evaluation for HCV+ patients; despite the increased role of
noninvasive tests for the evaluation of liver ﬁbrosis in HCV-
infected patients with CKD, this requires further study.
5.1. Kidney or Liver and Kidney Transplantation?
Should patients found to have advanced ﬁbrosis or cirrhosis
be excluded from kidney transplantation alone? This is a key
question as the mortality in HCV+ patients with advanced
kidney disease is more commonly related to other comor-
bidities than liver disease both pre- and posttransplantation
[39, 109] .T h ed a t ai nt h i sa r e aa r ec o n ﬂ i c t i n g .
The presence of compensated liver cirrhosis before
kidney transplantation has the potential to increase the
risk of recipient mortality in terms of operative procedure
because of marginal posttransplant reserve and nutritional
state, and increased susceptibility to post-transplant infec-
tious and metabolic complications, as well as evolution to
decompensated liver disease and the subsequent need for a
liver transplant.6 International Journal of Nephrology
Table 3: Predictive value of serological markers for advanced liver ﬁbrosis in HCV+ patients with end-stage renal disease.
Components of the test CutoﬀsA u t h o r s Sample
Size AUROC PPV NPV
APRI AST-to-Platelets-Ratio
<0.4 = no
advanced ﬁbrosis
>0.9 = advanced
ﬁbrosis
Schiavon et al.
[103] 203 0.8 66% 93%
Liu et al.
[104] 279 0.83 85% 82%
Schiavon et al.
[105] 185 0.78 66% 93%
Fibrotest
α2 macroglobulin, haptoglobin,
γ-glutamyl transpeptidase, total
bilirubin and apolipoprotein A1
levels
<0.2 = no
advanced ﬁbrosis
>0.6 = advanced
ﬁbrosis
Varaut et al.
[106] 50 0.47 71% 77%
Canabakan et al.
[107] 33 0.46 20% 45%
Hyaluronic
Acid
Unbranched, high-molecular
weight polysaccharide that is
widely distributed in the
extracellular spaces
<64 = no advanced
ﬁbrosis
>205 = advanced
ﬁbrosis
Schiavon et al.
[105] 185 0.65 42% 86%
YKL-40
Glycoprotein with function in
the remodelling of the
extracellular matrix or in tissue
inﬂammation
<290 = no
advanced ﬁbrosis
>520 = advanced
ﬁbrosis
Schiavon et al.
[105] 185 0.6 35% 84%
There arenodataavailabletodeterminewhetherpatients
with early cirrhosis on liver biopsy but well-compensated
clinical disease do better if they are transplanted or remain
on dialysis.
In 2006, Campbell et al. [109] evaluated the association
between advanced liver ﬁbrosis and survival among HCV+
patients evaluated for KT.
Among 108HCV+patients, eighteen(6%)had advanced
ﬁbrosis (bridging ﬁbrosis or cirrhosis) before KT. Fifty-
eight patients subsequently underwent KT, and 10 of these
had advanced ﬁbrosis. Rates of transplantation were similar
between those with advanced ﬁbrosis (56%) and those
without (53%; P = .1). Survival was similar in those
with and without advanced ﬁbrosis both among all patients
(P = .92) and among those patients who underwent kidney
transplantation (P = .83); nonliver disease comorbidities
seemed to be the most important outcome determinants in
this population.
In 2007, Maluf et al. [38], analyzing forty-three HCV+
KT recipients, identiﬁed Knodell score >6i nt h ep r e - K T
biopsies (without mentioning if it was prevalently related
to inﬂammation or ﬁbrosis) as a predictor of mortality
after KT in HCV+ve patients and, therefore, raised concerns
about the beneﬁts of KTx in this group of patients, although
prospective studies are necessary to conﬁrm these ﬁndings.
There are very limited outcomedataregarding transplan-
tation of a kidney alone in HCV-infected recipients with
pre-existing compensated cirrhosis of the liver; therefore,
the KDIGO (Kidney Disease: Improving Global Outcomes)
clinical guidelines2008 recommends that HCV-infected kid-
ney transplant candidates with compensated liver cirrhosis
on biopsy only be considered for kidney transplantation
under investigational protocol. HCV-infected patients with
evidence of decompensated liver disease should be evaluated
for simultaneous kidney liver transplantation [54].
6.Use ofKidneyAllograftsfrom
Anti-HCV+Donors
Shortly after the introduction of the ﬁrst-generation anti-
HCV tests, studies conducted at the New England Organ
Bank unequivocally demonstrated that HCV could be trans-
mitted by organ transplantation [110–112]. This may occur
as a new infection in a previously uninfected recipient or
superinfection with a diﬀerent genotype in an HCV-infected
recipient [113] Studies conducted in the 1980–1990s evi-
denced as, among recipients of organs from anti-HCV+ve
donors, 35% (range 0–55%) developed posttransplant liver
disease, 50% (14–100%) became anti-HCV+ve after trans-
plantation, and 73% (14–96%) developed HCV viremia
[111, 112]. The wide variations in the rate of transmission
of HCV infection by anti-HCV+ve donors reported by
diﬀerent centers could be due to several factors, such as
failure to test recipients at some centers, diﬀerent prevalence
of HCV infection among donors, and diﬀerences in organ
preservation;theuseofpulsatilepumpperfusionmayreduce
the viral load in the donor kidney and seems to have the
potential to reduce viral transmission from HCV-infected
organs [114]. The extrapolated prevalence of anti-HCV
among cadaver organs by ELISA-2 was calculated to be 4.2%
and that of HCV-RNA to be 2.4% [112]. This seems to
be higher than the prevalence of anti-HCV among healthy
blood donors, and it could reﬂect the higher prevalence of
riskfactors,amongcadaverorgandonors,associatedwiththe
spread of viral infections, such as unsuspected intravenous
drug use or sexual promiscuity.
The high prevalence of HCV among dialysis patients
awaiting KT and the shortage of cadaveric kidneys led some
groups to evaluate eﬃcacy and safety of using kidneys
from HCV+ donors in recipients infected with HCV [115,
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A large registry analysis in 2002 demonstrated that use of
grafts from HCV+ donors was associated with an increased
mortality, regardless of the anti-HCV antibody status of
the recipient [117]. However, the use of kidneys from anti-
HCV+ deceased donors in HCV+ recipients has been asso-
ciated with superior patient survival compared with dialysis
[118]. Also, Maluf et al. [119], using the Organ Procurement
and Transplantation Network (OPTN) database, reported
a shortened waiting time of nearly 300 days for HCV+ve
recipients received a graft from HCV+ donors compared
with HCV−ve recipients, though this was balanced by
a signiﬁcantly decreased patient and graft survival. It is
unknown whether the survival reduction was due to other
donor factors, a direct eﬀect of the virus on the kidney
itself, or related to superinfection with competing viral
strains.
AlargeranalysisofthesameOPTNdatabaserecentlyper-
formed by Northup et al. [120], including 19 496 HCV+ve
recipients and 934 HCV+ve donors, showed that the ad-
justed hazard ratio for death was similar for HCV+
recipient/HCV− donor compared with HCV+ recipi-
ent/HCV+ donor (1.176 versus 1.165, P = .91); the worst
survival was in the HCV− recipient/HCV+ donor group
(55.1%).
Use of organs from HCV+ donors has been associated
with severe acute hepatitis in HCV-ve recipients (fulminant
or ﬁbrosing cholestatic hepatitis), perhaps related to acute
infection under maximal immunosuppression [121–123],
increased prevalence of chronic liver disease, and worse
survival [35, 124–126]; therefore, transplantation of kidneys
from HCV+ donors should be restricted to recipients who
h a v eaH C Vv i r e m i aa tt h et i m eo ft r a n s p l a n t .
The potential risks ofsuperinfection with an HCVdonor
genotype diﬀerent from that of the recipient is unknown.
Genotype 1 is the most common genotype of hepatitis C
virus in the western countries in both patient with and
without ESRD, and it is known to be less responsive to
the antiviral therapy with Peg-interferon plus Ribavirin.
Genotype superinfection through transplantation has been
reported in a few cases, and an increase in transaminase
levels was observed [127–130]. Some authors argued that
genotyping should be routine, and that HCV genotype 1
kidneys should not be used in patients with other genotypes.
However, data donot exist for thisstrategy beyondanecdotal
reports, recommendations, and case reports.
In conclusion, these data provide strong evidence that
access to this “extra” pool of organs may confer a waiting
time advantage in the HCV-positive population, but the
conﬂicting data on graft and patient survival in this group
requires further thought.
7.TherapyofChronicHepatitisCinthe
ChronicKidneyDisease Population
In those without kidney disease, the current standard of care
for the treatment of HCV infection is with pegylated inter-
feron and ribavirin. The response is dependent on many
factors, including HCV genotype, HCV viral load, age and
gender, degree of liver impairment, and duration of therapy.
Treatment islimited by many factors, especially toxicity.New
agents, such as protease inhibitors, are in clinical develop-
ment and early studies suggest that these will revolutionize
the treatment of HCV infection. Thus, for some patients
with histologically early liver disease and little inﬂammatory
activity, delay of therapy may be appropriate.
Despite the increased prevalence of HCV infection in
CKD patients compared to that of the general population,
the indications for treatment and optimal antiviral regimens
in terms of safety and eﬃcacy in CKD are not well deﬁned.
Also, all major RCTs for the treatment of HCV infection
have speciﬁcally excluded patients with abnormal kidney
function. A variety of IFN-based regimens with diﬀering
treatment durations have been used in CKD, which makes
comparison among studies more diﬃcult. The KDIGO
Clinical Practice Guidelines 2008 on “Treatment of HCV
infection in patients with CKD”were based on the best avail-
able information from the CKD population together with
data from the general population, where extrapolation was
considered to be appropriate.
The decision to treat HCV infection in the CKD patient
should be based on liver histology, age, comorbidities, ability
to tolerate therapy, probability of achieve a sustained viral
response (SVR), life expectancy, and candidacy for kidney
transplantation [54].
Potential beneﬁts of successful therapy include slowing
the progression of liver disease and reducing the risk of post-
transplant complications associated with HCV. However,
giventhegenerallyindolentprogression ofHCV,treatmentis
not recommended forthe patient with less than a 5-year esti-
mated survival due to comorbidities such as cardiovascular
disease. In some patients,such asin thepretransplant patient
or in the patients with HCV-associated GN with or without
cryoglobulinemia, there are good data to support treatment.
For patients with HCV infection and CKD Stages 1–4, it
m i g h tb er e a s o n a b l et oa d a p tt h er e c o m m e n d a t i o n sf o r
treatment that apply to the general population, as there are
no studies available that target this speciﬁc population [54].
Considering thatHCV infection after kidneytransplantation
is implicated in the pathogenesis of acute glomerulopathy,
de novo graft HCV-associated GN, diabetes mellitus, and
the higher incidence of CAN, the strength of the recom-
mendation to treat HCV+ve kidney transplant candidate is
greater than in the general HCV+ve population on HD;
moreover, in this setting antiviral therapy is recommended
even for those with a pattern of histologic injury that does
not meet the recommended degree of ﬁbrosis to qualify for
therapy in the general population (that is, Metavir score
<2a n dI s h a ks c o r e<3). In patients with well-compensated
cirrhosis, the decision of whether to treat is diﬃcult,
and the beneﬁt of treatment in this setting is diﬃcult to
measure.
Conventional IFN monotherapy in dialysis patients with
chronic hepatitis Cis associated with dismal results [61,131–
136]. Two separate meta-analyses analyzing HCV+ patients
on hemodialysis showed SVR rates of 33% to 37% with
standard IFN-alpha with drop-out rates of 17% to 30%
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The combination of Pegylated IFN (PEG-IFN) and rib-
avirin (RBV) in chronic HCV patients with normal kidney
function gives reported SVR rates of 54% to 61% [139].
Few, studies have evaluated combined therapy in HD
patients and the quality of this evidence is very low [140–
147]. Patients with renal dysfunction are particularly vulner-
able to the tolerability issues associated with therapy with
PEG-IFN α plus ribavirin. The elimination rate of ribavirin
in patients with impaired renal function is reduced, and only
a small fraction of the drug is eliminated by hemodialysis. In
patientswith creatinine clearancebetween10–30mL/minute
and30–60mL/minute, theAUCforribavirin isthreefoldand
twofold greater, respectively, than for patients with CrCl >
90mL/minute. As a result of this increase in drug expo-
sure and the accompanying elevated risk for drug-related
toxicity, for example, severe hemolytic anemia, ribavirin is
contraindicated in patients with CrCl < 50mL/minute [148–
150].
The use of PEG-IFN monotherapy in patients with
ESRD, compared with traditional IFN, is more convenient
with once a week dosing, but only small studies have been
published to date [36, 151–160].
There is no signiﬁcant diﬀerence in apparent body clear-
ance of PEG-IFN α-2a between patients with normal kidney
function and those with signiﬁcant reductions in kidney
function (creatinine clearance >100mL/min versus 20–
40mL/min (CKD 3b/4)) [161]. However, with ESKD pa-
tients receiving HD, the pharmacokinetics of pegylated
interferon α-2a may vary reﬂecting diﬀerences in dialyzer
permeability and pore size [162]. Recently Fabrizi et al.
[163] attempted a systematic review of the literature with a
meta-analysis of clinical trials performed to assess eﬃcacy
and safety of PEG-IFN monotherapy in CKD patients with
chronic hepatitis C. They analyzed 16 clinical trials (5
controlled studies) with a total of 254 patients. The results
showed that SVR was achieved by around one-third of
patients on HD, the same response seen with standard IFN
monotherapy. However, the viral response to monotherapy
with standard or pegylated IFN in maintenance HD patients
remains higher than that observed in patients with chronic
hepatitis C virus and normal kidney function (7–29%) who
received standard IFN monotherapy [164]. There may be
several reasons for this including: low HCV viral load in
HD patients [165] reduced clearance of IFN in HD patients
[166]andtheobservationthatHCV-relatedchronichepatitis
in HD patients is usually milder [167]. The data reported
in this meta-analysis are limited by heterogeneity between
studies and the small numbers in each study population.
Furthermore, the applicability of these results to clinical
practice is uncertain because patients included in these
studies were on the waiting list for renal transplantation and
wereyoungerandprobablyhealthierthanthegeneraldialysis
population.
More encouraging results regarding the eﬀectiveness of
PEG-IFN come from the recent single-center report by
Werner et al. [168] who showed a SVR of 45% among
a population of 22 na¨ ıve HCV patients on HD listed
for KT, but conﬁrmation with larger samples is required
(Table 4).
Interferon therapy pretransplant has been associated to
a reduced incidence of post-transplant de novo or recurrent
glomerulonephritis. Cruzado et al. in 2003 [169]f o u n d
that of 15 HCV+ KT recipients who received prerenal
transplantation interferon, 10 (67%) became negative at the
time of renal transplantation, and only one of 15 (6.7%)
developedde novoglomerulonephritis(thispatientwasHCV
RNA+attransplantation). Amonguntreatedcontrols,12out
of 60 (19%) developed de novo glomerulonephritis post-KT,
all 12 had detectable HCV RNA at transplantation.
Pretransplant antiviral therapy of HCV may also reduce
theincidenceofpost-transplantdiabetesmellitus(PTDM)in
allograft recipients. In a controlled trial, Gursoy et al.[170]
observed that the frequency of PTDM was higher in the
group of HCV+ recipients who had not received IFN than in
those who had been treated with IFN before transplantation,
25% (10/40) versus 7.1% (1/14), P = .009.
8.Therapyof ChronicHCV Infectionin
KidneyTransplant Recipients
The eﬃcacy and safety of IFN-based therapy of hepatitis C
a f t e rK Ti su n s a t i s f a c t o r y[ 144, 171–174]. The potential ben-
eﬁtsneed to beweighed against therisk ofallograft rejection.
The administration of IFN after kidney transplantation
can be deleterious to the allograft and should generally
be avoided in kidney transplant recipients unless there is
indication ofworsening hepaticinjury onbiopsyorclinically
decompensating liver disease. Reported rates of kidney graft
dysfunction after IFN treatment range from 9 to 100%,
with most episodes occurring between 0.3 and 8 months
after initiation of therapy. Most kidney graft dysfunction
was related to increased rates of acute rejection, which is
frequently steroid resistant and irreversible and could lead to
graft loss [54].
Apart from the antiviral eﬀects mediated through the
Jak-Stat signaling pathway, IFN is a potent immunomodula-
toraﬀectingboththeinnateandtheadaptiveimmunesystem
[175–181].
The association between ACR and antiviral therapy
was initially described in renal transplant recipients and
was subsequently reported in liver transplant patients [182,
183]. Interferon alpha (IFNα) activates a large number
of interferon stimulated genes (ISGs), which combined
with the upregulation of MHC antigen expression results
in increased antigen presentation, T-cell activation, and
dominance ofaTh1 response includingrelease of TNFα,IL2,
IL12, IFNγ, FasL, perforin, and GrzB activities, and decrease
on IL10 and T-reg activity, collectively leading to tissue
damage and inﬂammation. Also, ribavirin potentiates ISGs
expression skewing toward TH response. IFNαalso enhances
recruitment and activity of other nonspeciﬁc cell types such
as natural killer (NK) cells, macrophages, neutophiles, and
monocytes.
While expansions of T-cell clones directed to viral anti-
gens contribute to viral load reduction and clearance,
expansions of T-cell clones to alloantigens may trigger im-
mune-related disordersincludingacutecellularrejectionandInternational Journal of Nephrology 9
Table 4: Clinical trials of monotherapy with conventional IFN or pegylated IFN in hemodialysis patients with chronic hepatitis C.
Period Patients
number Antiviral Agent Doses of IFN or Peg-IFN SVR
Degos et al. [132] 2001 37 IFN α 3MU three times weekly 19%
Mukherjee et al. [152] 2003 9 Peg-IFN-α2b 1mcg/kg/week 22%
Ozdemir et al. [133] 2004 20 IFN α 3–6MU three times weekly 40%
Rivera et al. [134] 2005 27 IFN α (n = 20)
Peg-IFN-α2a (n = 7)
3MU three times weekly
135mcg/week 40%
Mahmoud et al. [61] 2005 18 IFN α 3MU three times weekly 44%
Grgurevic et al. [135] 2006 15 IFN α
3 ×3MU/week (n = 8)
3 ×5MU/week for 3
months, then
1 ×5MU/week for another
3m o n t h s( n = 7)
40%
Rocha et al. [136] 2006 46 IFN α 3MU three times weekly 22%
Sporea et al. [153] 2006 10 Peg-IFN-α2a 180mcg/week 30%
Russo et al. [151] 2006 16 Peg-IFN-α2b 1mcg/kg/week (n = 9),
0.5mcg/kg/week (n = 7) 12.5%
Covic et al. [154] 2006 78 Peg-IFN-α2a 135mcg/week 14%
Espinosa et al. [36] 2007 16 Peg-IFN-α2a (n = 7)
Peg-IFN-α2b (n = 9)
1.5mcg/week (n = 9),
135mcg/kg/week (n = 7) 25%
Casanovas-Taltavullet al. [155] 2007 12 Peg-IFN-α2a 135 mcg/week 25%
Ucmak et al. [156] 2008 12 Peg-IFN-α2a 135mcg/week 50%
Sikoleet al. [157] 2008 14 Peg-IFN-α2a 135mcg/week 41%
Liu et al. [158] 2008 25 Peg-IFN-α2a 135mcg/week 48%
Ayaz et al. [159] 2008 22 Peg-IFN-α2a 135mcg/week 50%
Akhan et al. [160] 2008 12 Peg-IFN-α2a 135mcg/week 50%
Werner et al. [168] 2010 22 Peg-IFN-α2a (n = 9)
Peg-IFN-α2b (n = 13)
180mcg/week
1.5mcg/kg/week
1mcg/kg/week (1 patient)
45%
IFN: interferon; MU: million units; Peg-IFN: pegylated interferon; SVR: sustainedvirological response.
chronic ductopenic rejection as well as de novo autoimmune
hepatitis.
ACRisoftenassociated withconcomitantlowornegative
serum HCV RNA. It has been suggested that HCV clearance
during IFN-based therapy improves hepatic microsomal
function, which in turn leads to lower immunosuppressant
levelsin blood puttingpatients at higherrisk of development
of ACR.
The American Association for the Study of the Liver
Disease(AASLD)speciﬁcallyrecommends thatkidneytrans-
plantation is a contraindication to IFN therapy for HCV
infection. However, controlled and cohort (prospective or
retrospective) studies have addressed this issue in kidney
transplant recipients.
A meta-analysis of clinical trials of IFN-based therapy
(interferon alone or with ribavirin) in KT recipients with
chronic hepatitis C showed that the summary estimate for
SVR rate was 18.0% (95% CI, 7.0–29%) with a drop-out
rate of 35% (95% CI, 20–50%) [174]. The most frequent
side-eﬀect requiring discontinuation was acute rejection
refractory to corticosteroid therapy. Combined antiviral
therapy (interferon plus ribavirin) has been evaluated in a
few studies [172, 173]. Shu et al. [173] in 2004 reported
an SVR of 27% (3/11)and a drop-outrate of27% (3/11)due
to graft dysfunction (n = 1) and urosepsis (n = 2) during
antiviral therapy with very low dose IFN-α (1MU s.c. three
times weekly) for 48 weeks.
Thus, antiviral therapy with IFN,as state in KDIGOclin-
ical practice guidelines 2008, should only be considered in
patients with ﬁbrosing cholestatic hepatitis or life-threaten-
ing vasculitis in whom the risk of not treating justiﬁes the
possible loss of the allograft [54].
Alternative regimens based on amantadine, RBV mono-
therapy, or their combination have been proposed, but no
proof of their eﬃcacy has been provided [184–187], and
therefore they are not recommended.
9.Combined Kidney-LiverTransplantionin
PatientswithHepatitisC
As cirrhosis and the development of liver cell cancer consti-
tute an important risk factor for death and renal dysfunc-
tion after KT alone, combined kidney/liver transplantation
should be considered for KT candidates with cirrhosis.
Since the adoption of the Model for End-Stage Liver
Disease (MELD) score for allocating organs in the US in10 International Journal of Nephrology
2002, there has been a signiﬁcant increase in simultaneous
liver kidney (SLK) transplantation [188]. However, data are
controversial and do not identify which patient should be
oﬀered SLK transplantation [189–194].
In 2008 an American consensus conference [195]c o n -
venedtoestablishguidelinesforevaluation,listingandtrans-
plantation of patients with end-stage liver disease (ESLD)
and renal failure. The consensus agreed that the following
conditions represent clear indications for listing for SKL:
(i) End-stage renal disease with cirrhosis and symp-
tomatic portal hypertension or hepatic vein wedge
pressure gradient ≥10 mm Hg.
(ii) Liver failure and CKD with GFR ≤30 mL/min.
(iii) AKI or hepatorenal syndrome with serum creatinine
≥2.0mg/dL and dialysis ≥8 weeks.
(iv) Liver failure and CKD with a renal biopsy demon-
strating >30% glomerulosclerosis or 30% ﬁbrosis.
There are many data supporting the eﬀectiveness of SKL.
One year patient survival seems to be better than liver trans-
plantation alone (LTA) [190, 196]. Some evidence suggests
the kidney allograft lasts longer in liver transplant recipients
from the same donor [197, 198]. Moreover, dialysis seems to
be tolerated poorly in liver transplant recipients compared
with matched kidney failure only dialysis patients [199].
However, if patients with cirrhosis receive a liver and
kidneytransplant, thismay disadvantage those who requirea
kidney alone. Many recent studies have reported a lower sur-
vival of renal allografts in SLK compared to KTA recipients
without liver disease [189, 197, 200].
As HCV-related cirrhosis is the leading indication for liv-
er transplantation in western countries [201]a n db e c a u s e
HCV is associated with increased morbidity and mortality
among both liver and kidney transplant recipients [202–
207], there is a clear need to obtain data on the natural
history and management of recurrent hepatitis C in the SKL
setting.
In 2009, Del Pozo [208] compared outcomes among
HCV+ and HCV− recipients of SLK with HCV+ recipients
of isolated liver transplant, but did not ﬁnd any signiﬁcant
diﬀerence in terms of 1-, 2-, and 5-years survival (P =
.6). They found that HCV+ patients undergoing SKL
were signiﬁcantly older than HCV− patients (61 versus 51
years, P = .01). Diabetes after SLK was signiﬁcantly more
prevalent in the HCV+ group (78% versus 28%, P = .01).
There were no signiﬁcant diﬀerences between HCV+ and
HCV− SKL recipients in terms of kidney graft function and
kidney and liver rejection.
Van Wagner and colleagues [209], in the largest study
reported todate, analyzed the outcomeof patientswith HCV
infection undergoing SLK transplant, compared to that of
HCV+ patient underwent LTA.
Despite many limitations, such as the retrospective
nature of the studies, the heterogeneity of the indication for
SKL, the lack of a control group of HCV-SLK recipients, and
the choice of a control group of LTA patients with a lower
median MELD score lower (17.4 versus 38, LTA, and SLKT,
resp.), reﬂecting less advanced liver disease.
The 1-, 3-, and 5-year overall survival rates for the SLK
group were 73.7%, 61.8%, and 68.1%, and in the LTA
group the rates were 91.9%, 78.8%, and 73.2%, respectively.
However, once adjusted for age, gender, and MELD, there
were no statistical diﬀerences (P = .298). Also, there was
no diﬀerence in liver graft survival between SLK and LTA
groups.
There were more early posttransplant infection episodes
in the SLK (56.3%) compared with LTA (21.6%) (P = .001)
andtherewasatrendtowardsincreasedearlymortalityinthe
SLK group (P = .08), as reported in others studies [197, 200,
210–212].
There was no diﬀerence in the time to HCV recurrence,
the proportion with ≥stage 2 ﬁbrosis, renal function, and
graftfunctionbetweenthegroups.Thisstudydoesnotreport
posttransplant diabetes.
Tenofthe17SLKrecipientswithHCVrecurrenceunder-
went antiviral therapy with pegylated IFN and RBV. Of
these 10 SKL patients, two achieved SVR and 5 discontinued
therapy; of the 14 liver only recipients, 5 achieved SVR and
seven discontinued therapy. There were no episodes of liver
or kidney rejection while on treatment in the SKL group,
while one episode of liver rejection was documented in the
LTA group. The authors speculated that the simultaneous
transplantation of kidney and liver may protect the kidney
graft against acute rejection induced by PEG-IFN alpha
treatment; this is in keeping with evidence that the liver
transplant providessome level ofimmunologic protection to
the kidney allograft [197, 200].
Similar ﬁndings were reported in two case reports [213,
214] and in a small case series by Schmitz et al. [215],
who showed, among 6 recipients of combined kidney-liver
transplant (4 simultaneous, 2 consecutive), one episode of
liver rejection after antiviral treatment with PEG-IFN alfa2b,
butno episodes of kidney rejection were reported; the rate of
SVR was 50% (3/6).
Based on these data, antiviral treatment for HCV recur-
rence in SLK recipients appears safe, but additional prospec-
tive studies with larger patient populations are needed to
further validate the feasibility of such antiviral treatment.
10.Conclusion
The prevalence of hepatitis C in patients with chronic kidney
disease (CKD) on hemodialysis (HD) is higher than that in
the general population. Hepatitis C reduces survival both in
dialysis patients and renal transplant recipients. Liver biopsy
performed before KT is an important tool to determine the
severity of liver disease in HCV+ patients and may help to
assess the prognosis and the management of the patients
both before and after transplantation. Transplantation of
kidneys from HCV+ donors restricted to HCV+ recipients
may confer an advantage in terms of waiting time in
this population although the results on outcome seem to
be controversial. Monotherapy with conventional IFN or
Pegylated-IFN forchronic hepatitis C seems to beeﬀectivein
patientsonhaemodialysis. Dataavailableabout combination
therapy with pegylated interferon plus ribavirin are limited.International Journal of Nephrology 11
While IFN treatment in HCV+ kidney transplant candidates
is recommended, treatment post-KT should be restricted
to patients in whom the risk of not treating justiﬁes the
possible loss of the allograft (such as ﬁbrosing cholestatic
hepatitis). Otherwise, it is contraindicated, because of the
high risk of rejection and consequent graft loss. Simul-
taneous kidney/liver transplantation should be consid-
ered for renal transplant candidates with decompensated
cirrhosis.
Treatment of HCV recurrence in SLK recipients appears
eﬀective and safe, although further studies are needed to
validate this data.
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